Device Trial Radar · NCT01190306
Safety Study of the VEGA UV-A System to Treat Keratoconus
Last checked: Nov 20, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Topcon Medical Systems, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.
Conditions
- Keratoconus
Interventions
The VEGA UV-A Illumination SystemDevice
This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
RiboflavinDrug
Riboflavin is a solution that will be delivered to the treatment area
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Corneal Curvature.Time frame: 6 Months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.